Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of “Moderate Buy” by Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $5.67.

Several equities analysts have weighed in on the company. StockNews.com started coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They set a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday, July 31st.

Sangamo Therapeutics Price Performance

NASDAQ SGMO opened at $0.77 on Thursday. The company has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.62. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.48.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $8.51 million. During the same quarter last year, the business posted $0.12 earnings per share. On average, equities analysts expect that Sangamo Therapeutics will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SGMO. State Board of Administration of Florida Retirement System raised its stake in shares of Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the period. Mackenzie Financial Corp raised its stake in shares of Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 31,003 shares during the period. Golden State Equity Partners raised its stake in Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Sangamo Therapeutics during the 1st quarter valued at approximately $331,000. Finally, Assenagon Asset Management S.A. raised its stake in Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares during the period. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.